Decibel Therapeutics, Inc. Research and Development Expense
Decibel Therapeutics, Inc. reported Research and Development Expense of $12.83 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-08-11
- Decibel Therapeutics, Inc. research and development expense for the quarter ending 2023-06-30 was $12.83M, a 14.12% increase year-over-year.
- Decibel Therapeutics, Inc. research and development expense for the quarter ending 2023-03-31 was $7.93M, a 6.27% increase year-over-year.
- Decibel Therapeutics, Inc. research and development expense for the quarter ending 2022-12-31 was $11.59M, a 45.28% increase year-over-year.
- Decibel Therapeutics, Inc. research and development expense for the quarter ending 2022-09-30 was $10.03M, a 11.20% increase year-over-year.
- Decibel Therapeutics, Inc. research and development expense for fiscal 2022 was $40.33M, a 35.12% increase from fiscal 2021.
- Decibel Therapeutics, Inc. research and development expense for fiscal 2021 was $29.85M, a 17.87% increase from fiscal 2020.
- Decibel Therapeutics, Inc. research and development expense for fiscal 2020 was $25.32M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-06-30 | $12.83M 10-Q · filed 2023-08-11 | $20.76M 10-Q · filed 2023-08-11 | $32.35M derived: sum of 3 quarters · filed 2023-08-11 | $42.38M derived: sum of 4 quarters · filed 2023-08-11 |
| 2023-03-31 | $7.93M 10-Q · filed 2023-05-15 | $19.53M derived: sum of 2 quarters · filed 2023-05-15 | $29.56M derived: sum of 3 quarters · filed 2023-05-15 | $40.80M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-12-31 | $11.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $21.62M derived: sum of 2 quarters · filed 2023-03-14 | $32.86M derived: sum of 3 quarters · filed 2023-08-11 | $40.33M 10-K · filed 2023-03-14 |
| 2022-09-30 | $10.03M 10-Q · filed 2022-11-09 | $21.27M derived: sum of 2 quarters · filed 2023-08-11 | $28.74M 10-Q · filed 2022-11-09 | $36.72M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-06-30 | $11.24M 10-Q · filed 2023-08-11 | $18.71M 10-Q · filed 2023-08-11 | $26.69M derived: sum of 3 quarters · filed 2023-08-11 | $35.71M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $7.47M 10-Q · filed 2023-05-15 | $15.45M derived: sum of 2 quarters · filed 2023-05-15 | $24.47M derived: sum of 3 quarters · filed 2023-05-15 | $31.29M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $7.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $17.00M derived: sum of 2 quarters · filed 2023-03-14 | $23.83M derived: sum of 3 quarters · filed 2023-03-14 | $29.85M 10-K · filed 2023-03-14 |
| 2021-09-30 | $9.02M 10-Q · filed 2022-11-09 | $15.85M derived: sum of 2 quarters · filed 2022-11-09 | $21.87M 10-Q · filed 2022-11-09 | $29.76M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $6.83M 10-Q · filed 2022-08-10 | $12.85M 10-Q · filed 2022-08-10 | $20.74M derived: sum of 3 quarters · filed 2022-08-10 | $25.43M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $6.02M 10-Q · filed 2022-05-12 | $13.92M derived: sum of 2 quarters · filed 2022-05-12 | $18.61M derived: sum of 3 quarters · filed 2022-05-12 | $23.91M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $7.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $12.59M derived: sum of 2 quarters · filed 2022-03-18 | $17.89M derived: sum of 3 quarters · filed 2022-03-18 | $25.32M 10-K · filed 2022-03-18 |
| 2020-09-30 | $4.69M 10-Q · filed 2021-11-10 | $9.99M derived: sum of 2 quarters · filed 2021-11-10 | $17.43M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $5.30M 10-Q · filed 2021-08-10 | $12.73M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $7.44M 10-Q · filed 2021-05-13 |